Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Asset Writedowns and Impairment: 2020-2023

Historic Asset Writedowns and Impairment for Oncology Institute (TOI) over the last 4 years, with FY2023 value amounting to $2.0 million.

  • Oncology Institute's Asset Writedowns and Impairment rose 258783.78% to $2.0 million in Q4 2023 from the same period last year, while for Jun 2024 it was $2.0 million, marking a year-over-year increase of 262465.75%. This contributed to the annual value of $2.0 million for FY2023, which is 32436.97% up from last year.
  • Oncology Institute's Asset Writedowns and Impairment amounted to $2.0 million in FY2023, which was up 32436.97% from $476000.0 recorded in FY2022.
  • In the past 5 years, Oncology Institute's Asset Writedowns and Impairment ranged from a high of $7.5 million in FY2020 and a low of -$417000.0 during FY2021
  • For the 4-year period, Oncology Institute's Asset Writedowns and Impairment averaged around $2.4 million, with its median value being $1.2 million (2022).
  • Per our database at Business Quant, Oncology Institute's Asset Writedowns and Impairment crashed by 10556.0% in 2021 and then soared by 32436.97% in 2023.
  • Annual analysis of 4 years shows Oncology Institute's Asset Writedowns and Impairment stood at $7.5 million in 2020, then crashed by 105.56% to -$417000.0 in 2021, then skyrocketed by 214.15% to $476000.0 in 2022, then surged by 324.37% to $2.0 million in 2023.
  • Its Asset Writedowns and Impairment stands at $2.0 million for FY2023, versus $476000.0 for FY2022 and -$417000.0 for FY2021.